{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Single+Primary+Lung+Cancer", "query": { "condition": "Single Primary Lung Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Single+Primary+Lung+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-27T13:14:33.137Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07118176", "title": "Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anal Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Cholangiocarcinoma", "Colorectal Carcinoma", "Esophageal Carcinoma", "Gastric Carcinoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Lung Carcinoma", "Malignant Adrenal Gland Neoplasm", "Malignant Brain Neoplasm", "Malignant Neoplasm of Unknown Primary", "Malignant Solid Neoplasm", "Malignant Testicular Neoplasm", "Malignant Uterine Neoplasm", "Neuroendocrine Neoplasm", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Penile Carcinoma", "Pleural Carcinomatosis", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Salivary Gland Carcinoma", "Sarcoma", "Skin Carcinoma", "Solitary Fibrous Tumor", "Thymus Carcinoma", "Thyroid Gland Carcinoma", "Thyroid Gland Medullary Carcinoma", "Urothelial Carcinoma", "Vaginal Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Gallium Ga 68 FAPi-46", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-08-01", "completion_date": "2027-09-07", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07118176" }, { "nct_id": "NCT00611598", "title": "DNA Repair and Genetic Susceptibility to Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer", "Single Primary Lung Cancer", "Second Primary Lung Cancer" ], "interventions": [ { "name": "Blood draw and Questionnaires", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 218, "start_date": "2003-02-11", "completion_date": "2023-03-24", "has_results": false, "last_update_posted_date": "2023-03-29", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00611598" }, { "nct_id": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Carcinoma of the Appendix", "Estrogen Receptor-negative Breast Cancer", "Extensive Stage Small Cell Lung Cancer", "Gastrointestinal Stromal Tumor", "HER2-negative Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Progesterone Receptor-negative Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Small Intestine Adenocarcinoma", "Small Intestine Leiomyosarcoma", "Small Intestine Lymphoma", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Gastric Cancer", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Triple-negative Breast Cancer", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "7-hydroxystaurosporine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031681" }, { "nct_id": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anaplastic Thyroid Cancer", "Insular Thyroid Cancer", "Metastatic Parathyroid Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Parathyroid Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Thyroid Cancer", "Recurrent Verrucous Carcinoma of the Larynx", "Stage III Follicular Thyroid Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Non-small Cell Lung Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVA Basal Cell Carcinoma of the Lip", "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Lymphoepithelioma of the Oropharynx", "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVA Papillary Thyroid Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVB Basal Cell Carcinoma of the Lip", "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Lymphoepithelioma of the Oropharynx", "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVB Papillary Thyroid Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVC Basal Cell Carcinoma of the Lip", "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Lymphoepithelioma of the Oropharynx", "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVC Papillary Thyroid Cancer", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Thryoid Gland Nonmedullary Carcinoma", "Thyroid Gland Medullary Carcinoma", "Tongue Cancer", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-14", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068497" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT04276597", "title": "Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Neuroendocrine Neoplasm", "Pheochromocytoma", "Paraganglioma", "Thymus Carcinoid", "Unknown Primary Tumors", "Neuroendocrine Tumors", "Neuroendocrine Skin Carcinoma", "Neuroendocrine Breast Tumor", "Neuroendocrine Carcinoma Metastatic", "Neuroendocrine Neoplasm of Ovary" ], "interventions": [ { "name": "177Lu-DOTATOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Excel Diagnostics and Nuclear Oncology Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-03-04", "completion_date": "2021-07-15", "has_results": false, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276597" }, { "nct_id": "NCT05802186", "title": "Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Carcinoma", "Lung Non-Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Lung", "Stage I Lung Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiology, Treatment Planning", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-11-20", "completion_date": "2031-08-01", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05802186" }, { "nct_id": "NCT04076696", "title": "Clinical Evaluation of Primary Sampling Scatter Correction for Chest Tomosynthesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pulmonary Nodule, Solitary", "Pulmonary Nodule, Multiple" ], "interventions": [ { "name": "Scatter corrected s-DCT", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2020-08-26", "completion_date": "2021-08-26", "has_results": true, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04076696" }, { "nct_id": "NCT01638533", "title": "Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Hematopoietic and Lymphoid Cell Neoplasm", "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Neuroendocrine Neoplasm", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Colorectal Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Pancreatic Carcinoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage III Breast Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage III Lung Cancer AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Prostate Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Lung Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-08-03", "completion_date": "2020-09-01", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 11, "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01638533" }, { "nct_id": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "BNT116", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "BNT316", "type": "BIOLOGICAL" }, { "name": "anti-B7-H3 antibody conjugated to topoisomerase I inhibitor", "type": "BIOLOGICAL" }, { "name": "anti-HER3 antibody conjugated to topoisomerase I inhibitor", "type": "BIOLOGICAL" }, { "name": "Bispecific antibody for PD-L1 and VEGF-A", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "BIOLOGICAL" }, { "name": "ALK-inhibitor or RET-inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2022-06-17", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-06-27T13:14:33.137Z", "location_count": 5, "location_summary": "Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 2 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05142189" } ] }